Product Description
SHR3680 is a novel and pure androgen-receptor (AR) antagonist that shows a potent antitumor activity against CRPC but with much less brain distribution than enzalutamide in preclinical study.
Mechanisms of Action: AR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, China, Czech Republic, Poland, Unknown Location
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Prostate Cancer
Phase 2: Ductal Carcinoma
Phase 1: Hepatic Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SDC-1 | P2 |
Recruiting |
Ductal Carcinoma |
2029-03-30 |
|
| SHR3680-III-302 | P3 |
Recruiting |
Prostate Cancer |
2027-10-30 |
53% |
| IUNU-PC-119 | P2 |
Recruiting |
Prostate Cancer |
2027-03-01 |
|
| 2018-003190-96 | P3 |
Active, not recruiting |
Prostate Cancer |
2025-08-10 |